增加心血管疾病二次预防患者治疗坚持的干预措施的有效性:随机对照试验的研究方案
Francisco Manuel Lidón-Muñoz1, José Antonio Quesada2,3,4, Vicente Francisco Gil-Guillén2,3,4
1Dr. Balmis General University Hospital of Alicante, Babel Health Centre, Alicante, Spain.
Frontiers in medicine
|January 22, 2025
概括
改善心血管疾病患者的药物坚持是至关重要的. 基于慢性护理模型的健康教育干预表明,它有望提高对必要预防药物的坚持.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 卫生教育卫生教育教育
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因.
- 二次预防策略,包括抗高血压药物,他类药物和阿司匹林,至关重要,但面临着重大的坚持挑战.
- 不遵守处方药物很普遍,特别是在初级保健机构,导致发病率,死亡率和医疗保健成本增加.
研究的目的:
- 通过使用慢性护理模型,评估健康教育干预措施的有效性,以改善心血管二次预防的患者对三种关键预防药物的坚持.
- 解决高风险心血管疾病患者治疗不坚持的关键问题.
主要方法:
- 一个开放标签,随机对照试验,每组 (干预和控制) 有45名患者.
- 患者通过连续的非概率抽样选择,并使用随机数字表随机分配.
- 该研究涉及1年的随访期,计划进行单变量,双变量和多变量分析以评估数据.
主要成果:
- 该研究假设治疗坚持率从对照组的50%增加到干预组的80%.
- 统计功率设置为80%,I型错误率为5%.
- 在样本大小计算中,对随访的损失占15%.
结论:
- 如果成功,该干预措施提供了一个可行的方法,以提高心血管疾病二次预防患者在初级保健中的药物坚持.
- 改善的坚持可以显著减轻不坚持的负面后果,例如增加发病率和死亡率.
- 这种干预对管理全球主要死亡原因具有重大公共卫生影响.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
376
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
01:28Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:26Levels of Health Promotion and Illness Prevention
12.1K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
12.1K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:22Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K